A neurobehavioral signature of risk for mania
Philadelphia | July 11, 2023
Prediction could lead to better, earlier treatment according to new study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
Mania, in which mood and energy level are extremely elevated for at least a week, and hypomania, which is less severe and lasts at least four days, are the defining features of bipolar spectrum disorders (BSD) and can be the most disruptive symptoms. A new study(opens in new tab/window) in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging(opens in new tab/window), published by Elsevier, now identifies a signature of risk for developing future mania or hypomania.
BSD are psychiatric conditions that typically emerge in young adulthood, often severely disrupting lives and requiring intensive treatments. Mania risk has remained challenging for clinicians to predict; the ability to do so would aid in directing treatments to at-risk patients sooner.
The researchers, led by Adriane M. Soehner, PhD, at the University of Pittsburgh, built on previous research showing that heightened reward motivation and sleep-circadian rhythm disruption are associated with mania/hypomania onset. Brain imaging studies have also shown that BSD is associated with elevated reward expectancy activation in the left ventrolateral prefrontal cortex, a key reward- and salience-processing hub.
For the current study, Dr. Soehner and colleagues clustered these markers together; they hypothesized that a signature of increased mania risk would be marked by elevated reward sensitivity, impulsivity, and sleep-circadian characteristics. Young adult participants, who did not have a diagnosis of BSD, completed assessments and underwent functional magnetic resonance imaging. About half the participants also underwent follow-up assessments at six and 12 months.
Three “profiles” emerged from the sample: one healthy, one at moderate risk, and one at high risk. Individuals at high risk had elevated mania symptoms at baseline compared to the other two groups. Over the 12-month follow-up interval, mania symptoms in both the high-risk and moderate-risk groups exceeded the healthy group.
Dr. Soehner said of the findings, “Here, we identified neurobehavioral profiles based on reward sensitivity, impulsivity, and sleep-circadian characteristics that help distinguish those with elevated mania vulnerability. These characteristics, in combination, may help detect mania risk and provide targets to guide and monitor early interventions.”
Cameron Carter, MD, Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, said of the work, “New findings such as these highlight our emerging ability to combine neurobiological and clinical measures to identify groups of patients at highest risk for serious mental health problems such as mania, allowing for early identification and intervention for those at highest risk. Future research is needed to show that this can lead to reduced suffering and better outcomes in individuals identified in this way.”
Notes for editors
The article is "Neurobehavioral Reward and Sleep-Circadian Profiles Predict Present and Next-Year Mania/Hypomania Symptoms," by Adriane M. Soehner, Meredith L. Wallace, Kale Edmiston, Henry Chase, Jennette Lockovich, Haris Aslam, Richelle Stiffler, Simona Graur, Alex Skeba, Genna Bebko, Osasumwen E. Benjamin, Yiming Wang, and Mary L. Phillips (https://doi.org/10.1016/j.bpsc.2023.04.012(opens in new tab/window)). It appears as an Article in Press in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging(opens in new tab/window), published by Elsevier(opens in new tab/window).
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 254 522 9700 or [email protected](opens in new tab/window). Journalists wishing to interview the authors may contact Ashley Tentrock at [email protected](opens in new tab/window).
The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.
Cameron S. Carter, MD, is Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis. His disclosures of financial and conflicts of interests are available here(opens in new tab/window).
About Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging(opens in new tab/window) is an official journal of the Society of Biological Psychiatry(opens in new tab/window), whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches. The 2022 Journal Impact FactorTM score, from Clarivate, for Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is 5.9.www.sobp.org/bpcnni(opens in new tab/window)
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses.
Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, medical education, and nursing education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet(opens in new tab/window) and Cell(opens in new tab/window); 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation(opens in new tab/window) and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers.